Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

413
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
413
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

406
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
406
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

383
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
383
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

398
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
398
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

567
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
567
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

581
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
581

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An unusual presentation of a gastric gastrointestinal stromal tumor as a chronic contained perforation with concomitant Helicobacter pylori infection: A case report and literature review.

International journal of surgery case reports·2025
Same author

Patient and clinician perceptions of the trauma and acute care surgery hospitalization discharge transition of care: a qualitative study.

Trauma surgery & acute care open·2022
Same author

Incorporating harms into the weighting of the revised Agency for Healthcare Research and Quality Patient Safety for Selected Indicators Composite (Patient Safety Indicator 90).

Health services research·2021
Same author

Association of Hospital-Level Intensive Care Unit Use and Outcomes in Older Patients With Isolated Rib Fractures.

JAMA network open·2020
Same author

Repeat computed tomography head scan is not indicated in trauma patients taking novel anticoagulation: A multicenter study.

The journal of trauma and acute care surgery·2020
Same author

Hospital-level intensive care unit admission for patients with isolated blunt abdominal solid organ injury.

The journal of trauma and acute care surgery·2020

Related Experiment Video

Updated: Jan 3, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.3K

Evolving Strategies to Manage Clostridium difficile Colitis.

Jessica A Bowman1, Garth H Utter2,3

  • 1Department of Surgery, University of California, Davis, Medical Center, 2335 Stockton Blvd., Sacramento, CA, 95817, USA.

Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|November 27, 2019
PubMed
Summary

Clostridium difficile infection (CDI) management has evolved, with vancomycin as preferred first-line treatment. New therapies like fidaxomicin, bezlotoxumab, and fecal microbiota transplantation offer options for recurrent CDI, while less invasive surgery is explored for severe cases.

Keywords:
Clostridium difficile colitisPseudomembranous colitis

More Related Videos

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.8K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K

Related Experiment Videos

Last Updated: Jan 3, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.3K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.8K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K

Area of Science:

  • Infectious Diseases
  • Gastroenterology
  • Surgical Innovation

Background:

  • Clostridium difficile infection (CDI) is a significant nosocomial pathogen.
  • Elderly patients with comorbidities and recent antibiotic exposure are most affected.
  • Evolving understanding of CDI transmission and virulence drives changes in care.

Purpose of the Study:

  • To review recent advancements in CDI diagnostics and treatment strategies.
  • To highlight current preferred therapies and emerging options for CDI management.
  • To discuss the role and challenges of operative intervention in severe CDI.

Main Methods:

  • Review of current literature on Clostridium difficile infection.
  • Analysis of updated diagnostic and therapeutic guidelines.
  • Evaluation of novel antimicrobial agents, monoclonal antibodies, and surgical approaches.

Main Results:

  • Oral or enteral vancomycin is the preferred first-line treatment for CDI.
  • Fidaxomicin, bezlotoxumab, and fecal microbiota transplantation are valuable for recurrent CDI.
  • Less invasive surgical options like laparoscopic diverting ileostomy show promise for frail patients.

Conclusions:

  • Modern CDI treatment incorporates vancomycin, fidaxomicin, bezlotoxumab, and FMT.
  • Surgical intervention is reserved for fulminant CDI, with less invasive options emerging.
  • Continued research is crucial for optimizing CDI patient outcomes.